Akèy › Kansè pwostat › Massachusetts › Boston
Etid klinik pou Kansè pwostat nan Boston, MA
59 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Ap rekrite
- Dana-Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
Ap rekriteFaz 4
- Massachusetts General Hospital, Boston
Precision-Based Genomics in Prostate Cancer
Ap rekriteEtid obsèvasyon
- Dana Farber Cancer Institute, Boston, MA, Boston
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Ap rekrite
- Dana Farber Cancer Institute, Boston
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Ap rekriteFaz 1/2
- Research Site, Boston
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Ap rekriteFaz 1/2
- Dana Farber Mass General Brigham Cancer Care Inc, Boston
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- Harvard Medical School-Massachusetts General Hospital, Boston
Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes
Ap rekrite
- Dana-Farber Cancer Institute, Boston
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Ap rekriteFaz 2/3
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Ap rekriteFaz 1
- Mass General Hospital, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Ap rekriteFaz 3
- Beth Israel Deaconess Med Center, Boston
- Dana Farber Cancer Institute, Boston
CV CARE: CardioVascular Care in PC Patients
Ap rekrite
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Ap rekriteFaz 3
- Beth Israel Deaconess Medical Center ( Site 0043), Boston
- Dana Farber Cancer Institute ( Site 0012), Boston
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Ap rekriteFaz 3
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
Ap rekrite
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Serial MRI Scans During Radiation Therapy
Ap rekrite
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Prostate Active Surveillance Study
Ap rekriteEtid obsèvasyon
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
Ap rekriteFaz 2
- Dana Farber Cancer Institute, Boston
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
Ap rekriteFaz 2
- Brigham and Women's Hospital, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Ap rekriteFaz 2
- Dana-Farber Cancer Institute / Beth Israel Deaconess Medical Center, Boston
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Boston
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
Ap rekriteFaz 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
Ap rekrite
- Dana Farber Cancer Institute, Boston
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
Ap rekriteFaz 3
- Dana-Farber Cancer Institute, Boston
Jump: MR Simulation For Radiation Therapy Master Protocol
Ap rekrite
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
Ap rekriteFaz 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Video Education With Result Dependent dIsclosure
Ap rekrite
- Dana Farber Cancer Institute, Boston
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
Ap rekriteFaz 3
- Brigham and Women's Hospital, Boston
- Brigham and Women's Faulkner Hospital, Boston
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Ap rekriteEtid obsèvasyon
- Dana-Farber Cancer Institute, Boston
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Massachusetts General Hospital, Boston
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
Ap rekriteEtid obsèvasyon
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- Research Site, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
Clinical Trial of Approaches to Prostate Cancer Surgery
Ap rekrite
- Beth Israel Deaconess Medical Center (BIDMC), Boston
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute, Boston
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Ap rekriteFaz 2/3
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Ap rekriteFaz 1/2
- Research Site, Boston
- Research Site, Boston
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Ap rekriteFaz 4
- Dana Farber Cancer Institute, Boston
- Brigham and Womens Hospital, Boston
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Ap rekriteFaz 4
- Massachussets General Hospital, Boston
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
Ap rekriteVolontè an sante akeyi
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
MRI Guided Prostate Biopsy
Ap rekrite
- Brigham and Women's Hospital, Boston
Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
Ap rekriteEtid obsèvasyon
- Massachsuetts General Hospital, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
Ap rekrite
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer
Ap rekriteVolontè an sante akeyi
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
- Brigham and Womens Hospital, Boston
Comprehensive Outcomes for After Cancer Health
Ap rekriteVolontè an sante akeyi
- Dana Farber Cancer Institute, Boston
ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer
Ap rekriteEtid obsèvasyon
- Massachusetts General Hospital, Boston
Prostate Cancer Genetic Risk Evaluation and Screening Study
Ap rekriteEtid obsèvasyon
- Massachusetts General Hospital, Boston
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Nashville, TN42 etid
- Seattle, WA42 etid
- Washington, DC38 etid
- Dallas, TX36 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)86 etid
- Kansè kolorektal63 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
- Kansè pankreyas43 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.